We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Ramipril Patent Invalid Due To Obviousness: Court

Law360 (September 11, 2007, 12:00 AM EDT) -- An appeals court ruled on Tuesday that King Pharmaceutical's patent on its hypertension drug Altace was obvious and thus invalid, overturning a lower court's ruling that generics maker Lupin LTD infringed on the patent.

King, along with German drug maker Aventis Pharma Deuschland GMBH, originally filed a suit against Lupin after Lupin filed an Abbreviated New Drug Application to make a generic version of Altace.

A Virginia district court ruled last year that Lupin's generic drug would have infringed, though it dismissed King and Aventis' claim...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.